Physician profile
Ryan T Frank
NPI 1720373061
$4,378.27
in general payments reported to CMS, 2019-2025
36 companies · $584 in 2025
The $584 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $673 · 2021: $685 · 2022: $437 · 2023: $859 · 2024: $686 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $959.95 | 2019-2025 | Farxiga |
| Abbvie INC. | $851.56 | 2019-2025 | |
| Novo Nordisk INC | $472.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ethicon INC. | $208.71 | 2023 | Monarch Platform |
| Janssen Pharmaceuticals, INC | $183.83 | 2019-2024 | Xarelto |
| Allergan, INC. | $182.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.13 | 2020-2025 | Jardiance |
| W. L. Gore & Associates, INC. | $159.09 | 2024 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Pfizer INC. | $128.64 | 2020-2025 | |
| Glaxosmithkline, LLC. | $127.37 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $112.80 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $111.78 | 2020-2024 | |
| Astellas Pharma US INC | $97.25 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $68.81 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $62.74 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.47 | 2021-2024 | Xifaxan, Trulance |
| Jazz Pharmaceuticals INC. | $37.71 | 2021 | |
| Lifescan, INC. | $32.35 | 2023 | |
| Sanofi-Aventis U.S. LLC | $31.27 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.04 | 2022 | |
| Dexcom, INC. | $26.23 | 2023 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $26.09 | 2021 | |
| Genentech USA, INC. | $24.23 | 2021 | |
| Amgen INC. | $23.88 | 2022 | |
| Dermira, INC. | $23.73 | 2020 | |
| Amarin Pharma, INC. | $20.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.57 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.19 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $18.23 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.42 | 2021 | |
| Hikma Pharmaceuticals USA | $16.72 | 2019 | |
| Adlon Therapeutics L.P. | $15.45 | 2019 | |
| Ibsa Pharma INC. | $15.44 | 2020 | |
| Exeltis, USA INC. | $14.64 | 2024 | Slynd |
| Ironwood Pharmaceuticals, INC | $14.55 | 2019 | |
| Clarus Therapeutics INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.